Liquid Biopsy in Breast Cancer
Autor: | Maggie Banys-Paluchowski, Tanja Fehm, Natalia Krawczyk |
---|---|
Jazyk: | angličtina |
Rok vydání: | 2020 |
Předmět: |
Oncology
medicine.medical_specialty medicine.medical_treatment Context (language use) Disease zielgerichtete Therapie Targeted therapy Mammakarzinom zirkulierende Tumor-DNA 03 medical and health sciences 0302 clinical medicine Breast cancer breast cancer Internal medicine Maternity and Midwifery medicine Review/Übersicht GebFra Science Liquid biopsy PI3K/AKT/mTOR pathway 030304 developmental biology 0303 health sciences liquid biopsy business.industry circulating tumour DNA Obstetrics and Gynecology zirkulierende Tumorzelle medicine.disease targeted therapy Response to treatment Metastatic breast cancer 030220 oncology & carcinogenesis circulating tumour cell business |
Zdroj: | Geburtshilfe und Frauenheilkunde |
ISSN: | 1438-8804 0016-5751 |
Popis: | In recent years, the blood-based analysis of circulating tumour cells (CTCs) and nucleic acids (DNA/RNA), otherwise known as liquid biopsy, has become increasingly important in breast cancer. Numerous trials have already underscored the high prognostic significance of CTC detection in both early and metastatic stages. Moreover, the changes in CTC levels and circulating tumour DNA (ctDNA) during the course of the disease correlate with the response to treatment. Research currently focuses on liquid-biopsy based therapeutic interventions in metastatic breast cancer. In this context, alpelisib, a PI3K inhibitor, was the first agent to be approved by FDA and EMA. |
Databáze: | OpenAIRE |
Externí odkaz: |